Member Info for Killery

Following on from a previous study that shows about a quarter have heart damage after recovering from Covid, this is very alarming and could lead to further problems for the NHS down the road. It shows how dangerous the cytokines storm is and that we should not wait for a deteriorating health condition before acting. At first proof of Covid infection the NHS should commence treatment by giving SNG 001 and Leronlimab. The former immediately helping with breathing and the latter preventing the cytokines storm from starting ( by day 3) and allowing the body,s own immune system to destroy the virus by day 14.

Some of this plasma will still have Rantes and cytokines in it so whilst some will survive, some/ many of those will have to endure months of aches and bad flu type symptoms unless they are given Leronlimab in which case why don’t they just give it instead from the outset.

Rumour coming out of Washington DC is it is not Cytodyn and is a company with FDA conections( surprise,surprise!) and has an EUA in place.

OMG the whole world knows about Adam Feurstein and his famous shorting raids. Please show some credibility as you are embarrassing yourself.

Lots of people are getting over excited about tonight’s Covid statement so I will try to let them down gently:
1. Do you really think the FDA are going to approve a non American company with a successful trial on only 30 patients. It could happen in India but nowhere else.
2. Trump lost of credibility for promoting Hyroxychloroquine only for the FDA to ban it as unsafe. It has known risks but it is not unsafe and is used daily by tens if not hundreds of millions of people. Also doctors around the world are having great success against Covid using Hydroxychlorine,Azithromycin and zinc when given as ****tail withIn 5 to 7 days of getting Covid. In recent weeks there has representations made to the FDA ( see open letter to Fauci) to rescind their ban and if they did it would give Trump a big boost.
3. Operation Warp Speed has approached Cytodyn

OK point taken but just to answer your question. Please do not under estimate the damage these cytokines may be doing and may lead to further health problems for the NHS down the road. Recent research has shown that 25% of people who have recovered from Covid ( even when they have had no symptoms) has shown that they have heart damage which they think is from the cytokines ( note they only looked at the heart so the picture may be much wider ???) . Also don’t forget cytokines storms result in every day mortalities such as flu and sepsis.So we now know the mechanism ( thanks to Bruce Patterson - listen to his TED talk) and Synergen and Leronlimab together will give a quick solution/ treatment.

Blocking the CCR5 receptor, stops the cytokine storm, allows the immune system to recover which then naturally kills the invading or virally infected cells be it Covid (within two weeks) or tumor metastases.
Leronlimab has shown no significant side effects, in more than 1,000 patients over six years.
Treating the mild to moderate cases in a trial is very difficult as many patients appear to naturally get better after a number of weeks. Leronlimab proved significant improvement is these patients in such a trial by reducing the number of seriously sick events by 64% and seriously improving their NEWS2 score (i.e. a clinical way of showing their improved health). They showed significant health improvement as early as day 3 which is important as it means the cytokines are reducing, their immune systems are getting better stopping the cytokines from causing serious hidden damage to peoples organs, and identifying patients at an early stage who will need closer attention. As a result of this trial Cytodyn has filed for Emergency Use Authorization in a number of countries (including UK) for leronlimab in covid-19 disease.
RANTES and immune dysregulation results in chronic inflammation and dozens of diseases affecting millions of patients. These include multiple sclerosis, Alzheimer's, Parkinson's, lupus, crohn's disease, amyolateral sclerosis, Guillan-Barre and symptoms of post-Lyme infection, Amyolateral sclerosis (Lou Gehrig’s Disease) and over 30 types of cancer. As an aside, leronlimab also apparently blocks tumor metastases in a number of solid tumor cancers, including breast, prostate, colon and bladder. In an initial trial of 12 women with Tnbc (triple negative breast cancer, meaning cancer tumor cells without any of the three common cell proteins targeted by chemotherapy, with a resultant grave prognosis), circulating tumor cells went to ZERO. This means that metastasis was stopped in its tracks. Metastasis is what causes death in 90% of solid tumor cancers.
Cytodyn are currently running a phase 3 blind trial to see the survival of 195 severe to critical patients treated with Lironlimab after 30 days. They currently have 183 patients and UK MHRA have agreed to participate in the trial so that should accelerate the results.
The Management is doing an amazing job fighting against many dark forces and successfully delivering on an incredible number of fronts. They are hoping to uplist to Nasdaq in the coming weeks/month.

The following explains in simple terms what happens in a Covid/ HIV attack. When a virus invades the body, it infects and kills cells, as it hijacks the cellular apparatus to replicate itself. Injured and infected cells respond to this attack by releasing cytokines, which are chemical messengers which "call for help", initiating an inflammatory response to fight the infection. A subset of cytokines are chemokines (chemotaxic cytokines), which mobilize infection fighting cells to areas of tissue damage and inflammation.
One of the principal chemokines in the activation of the immune system is CCL5 or RANTES. RANTES is released by a number of cell types, but in Covid infection, it is importantly released by injured epithelial cells in the lungs. White blood cells, including T cells and macrophages respond to the site of infection. Unfortunately in severe Covid disease, the injured cells continue to release RANTES. More inflammatory cells migrate to areas of inflammation, creating a vicious circle, eventually escalating to the "cytokine storm". The excess migration of these cells to the lungs is a large component of the acute respiratory distress syndrome and pulmonary collapse in severe covid. A cascade of other cytokines are released as part of an inflammatory cascade, including interleukin 6 and TNF-alpha, which have been the target of other unsuccessful Covid treatments. The combination of extreme cytokine levels and excess activation and mobilization of inflammatory cells results in a profound immune dysregulation. This is profoundly injurious and eventually deadly.
Excess stimulation of the cytokine storm eventually exhausts the ability of these immune fighting cells to function properly. Macrophages, a type of white blood cell, become polarized and act in an inflammatory fashion, rather than helpfully devouring viruses and infected cells. T cells, rather than producing granzyme-a, an important enzyme to kill infected cells, lie about helplessly.
Leronlimab is a therapeutic monoclonal antibody which is on the cusp of approval, with blockbuster, if not paradigm-shifting potential.
Leronlimab is a monoclonal antibody, which was designed to treat HIV. It blocks the binding site (the doorway) on the CCR5 receptor, the primary site to which CCL5/RANTES binds. Leronlimab is awaiting approval for HIV. The HIV virus enters T cells through CCR5, infecting and killing them and destroying a major part of the immune system. Leronlimab "blocks this door", preventing HIV entry, and returning patients to health. Trial patients have had undetectable levels of HIV virus for six years while taking leronlimab, all without taking any antiviral medication. The immune system, when not damaged, clears the virus by itself.
In covid, administration of leronlimab blocks the same CCR5 receptor. By blocking CCR5, immune cells no longer migrate to areas of inflammation, preventing runaway inflammation and reversing the disproportionate inflammation of the cytokine st

All posts on this are wrong. He is probably referring to Cytodyn . have a read:

BREAKING NEWS. - CytoDyn reports exciting news from its top line Phase II trial data using Leronlimab!



Results place drug in lead position as a potential cure of all therapeutic treatments for COVID. Complete data now being forwarded to FDA (and to Uk and Euro regulatory bodies) for detailed analysis and potential consideration for Emergency Use Authorization to treat the deadly disease.



- Leronlimab repeatedly proven safe with little to no side effects in EIND use, HIV trials, Severe/Critical trial and now Phase II application.



- Patients receiving Leronlimab show 50% improvement in prevention of severe and other adverse effects vs.those taking placebo



- Drug meets Day 3 primary endpoint showing immediate health improvement for recipients in double blind study.



- Day 14 National Emergency Warning Scores (NEWS) twice as good in those receiving Leronlimab vs. those on placebo.



- Findings demonstrate Leronlimab reduces chance of patients advancing to hospitalization potentially saving thousands of lives and millions in healthcare costs to governments worldwide.



- CytoDyn will also hold a press briefing to answer investor’s questions today at 9PM BST



Here is a link to hear Dr Yo’s interview with Dr Bruce Patterson about Cytodynes Phase 2 results:

https://www.youtube.com/watch?v=horRSvu6xAk



In this interview he states:

· The Leromlimab trial shows significant results in the Mild to Moderate(M to M) Covid patients over the placebo branch receiving the current Standard of Care.

· The compelling info and data of the trials will make a strong case for the application to the FDA especially as no other med has shown significant treatment for the M to M cohort.

· The trials show that Lero provides immunological restoration very early (day 3) quieting the cytokine storm.

· Lero will significantly reduce hospital stay in the M to M from 14 days to possibly 3 days (as they will feel better). The FDA should look favourably on this this as it will save huge hospital costs.

· This huge clinical study confirms Incelldx’s studies of the mechanism of action of Lero.

· Incelldx is about to open a lab in the UK and will provide a full diagnostic service ( also for you Long Haulers, Peter).

· Bruce Patterson’s paper on Rantes in the EIND patients ( i.e. the emergency treatment of critically ill patients previously treated with Lero) is about to be published.